↓ Skip to main content

Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent

Overview of attention for article published in Journal of Translational Medicine, December 2014
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (71st percentile)
  • Good Attention Score compared to outputs of the same age and source (72nd percentile)

Mentioned by

twitter
1 X user
patent
1 patent
facebook
1 Facebook page

Citations

dimensions_citation
80 Dimensions

Readers on

mendeley
50 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent
Published in
Journal of Translational Medicine, December 2014
DOI 10.1186/s12967-014-0356-1
Pubmed ID
Authors

Francesca del Bufalo, Andrea Carai, Lorenzo Figà-Talamanca, Benedetta Pettorini, Conor Mallucci, Felice Giangaspero, Manila Antonelli, Manuela Badiali, Loredana Moi, Giuseppe Bianco, Antonella Cacchione, Franco Locatelli, Elisabetta Ferretti, Angela Mastronuzzi

Abstract

BackgroundGanglioglioma (GG) and pilocytic astrocytoma (PA) represent the most frequent low-grade gliomas (LGG) occurring in paediatric age. LGGs not amenable of complete resection (CR) represent a challenging subgroup where traditional treatments often fail. Activation of the MAP Kinase (MAPK) pathway caused by the BRAFV600E mutation or the KIAA1549-BRAF fusion has been reported in pediatric GG and PA, respectively.Case presentationWe report on a case of BRAFV600E mutated cervicomedullary GG treated with standard chemotherapy and surgery. After multiple relapse, BRAF status was analyzed by immunohistochemistry and sequencing showing a BRAFV600E mutation. Treatment with Vemurafenib as single agent was started. For the first time, a radiological and clinical response was obtained after 3 months of treatment and sustained after 6 months.ConclusionOur experience underline the importance of understanding the driver molecular alterations of LGG and suggests a role for Vemurafenib in the treatment of pediatric GG not amenable of complete surgical resection.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 50 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 2%
France 1 2%
Italy 1 2%
Unknown 47 94%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 8 16%
Student > Bachelor 7 14%
Researcher 7 14%
Other 6 12%
Student > Master 6 12%
Other 6 12%
Unknown 10 20%
Readers by discipline Count As %
Medicine and Dentistry 16 32%
Biochemistry, Genetics and Molecular Biology 5 10%
Agricultural and Biological Sciences 5 10%
Neuroscience 3 6%
Nursing and Health Professions 2 4%
Other 6 12%
Unknown 13 26%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 March 2021.
All research outputs
#6,945,280
of 22,775,504 outputs
Outputs from Journal of Translational Medicine
#1,085
of 3,984 outputs
Outputs of similar age
#95,404
of 353,125 outputs
Outputs of similar age from Journal of Translational Medicine
#35
of 139 outputs
Altmetric has tracked 22,775,504 research outputs across all sources so far. This one has received more attention than most of these and is in the 68th percentile.
So far Altmetric has tracked 3,984 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.5. This one has gotten more attention than average, scoring higher than 71% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 353,125 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
We're also able to compare this research output to 139 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.